Discovery of a highly potent novel rifampicin analog by preparing a hybrid of the precursors of the antibiotic drugs rifampicin and clofazimine
Abstract Tuberculosis (TB) is an infectious disease caused by the bacillus Mycobacterium tuberculosis (Mtb). The present work reports the design and synthesis of a hybrid of the precursors of rifampicin and clofazimine, which led to the discovery of a novel Rifaphenazine (RPZ) molecule with potent a...
Main Authors: | Pasupathy Saravanan, V. N. Azger Dusthackeer, R. S. Rajmani, B. Mahizhaveni, Christy R. Nirmal, Sam Ebenezer Rajadas, Neerupma Bhardwaj, C. Ponnuraja, Adhin Bhaskar, A. K. Hemanthkumar, Geetha Ramachandran, Srikanth P. Tripathy |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2021-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-020-80439-2 |
Similar Items
-
Dodecanoic acid & palmitic acid disarms rifampicin resistance by putatively targeting mycobacterial efflux pump Rv1218c
by: Christy Rosaline Nirmal, et al.
Published: (2023-01-01) -
Clofazimine, but Not Isoniazid or Rifampicin, Augments Platelet Activation in vitro
by: Ronald Anderson, et al.
Published: (2018-11-01) -
Adverse reactions induced by MDT/WHO (Rifampicin+Clofazimine+Dapsone) and ROM (Rifampicin+Ofloxacin+Minocycline) regimens used in the treatment of leprosy: a cohort study in a National Reference Center in Brazil
by: Isadora Costa Celestino, et al.
Published: (2024-03-01) -
Wild-Type MIC Distribution for Re-evaluating the Critical Concentration of Anti-TB Drugs and Pharmacodynamics Among Tuberculosis Patients From South India
by: Azger Dusthackeer, et al.
Published: (2020-06-01) -
Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
by: Xingshan Cai, et al.
Published: (2022-11-01)